2 Marvelous Marijuana Stocks in the Making

Alcanna Inc. (TSX:CLIQ) and The Supreme Cannabis Company, Inc. (TSXV:FIRE) might be unheralded but both are absolutely marvelous marijuana stocks in the making.

Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

The controversies involving the big cannabis players shouldn’t distract you. Otherwise, you’ll lose sight of the smaller but marvelous marijuana stocks in the making. Alcanna (TSX:CLIQ) and Supreme Cannabis (TSXV:FIRE) are quietly making the right moves in the sidelines.

Both companies are gearing up to gain headway in Canada’s direct cannabis market that will be worth $11 billion in the next six years. You need to keep watch of these companies whose business models are dynamic and growth-oriented.

Transformed business

Alcanna is dominating the retail liquor business in Canada. The company posted a third straight quarter of steady market share gains. There was a 20.9% growth in sales and an 8.2% growth in same-store sales in the three and six months ended June 30, 2019 compared with the same period in 2018.

James Burns, Alcanna’s Vice Chairman, and CEO said the company is working to re-establish market foothold after losing it to competitors. Alcanna is competing but slowly adapting to the low gross margin environment. Selective margin enhancement will begin in the second half of 2019 when Alcanna regains market share.

The company has nine retail cannabis stores under the brand Nova Cannabis. The construction of other stores is ongoing, and the target is to have an additional 15 to 20 stores by year-end. Alcanna is also converting some of its liquor stores to retail cannabis stores.

Entry into the cannabis world would strengthen Alcanna’s balance sheet as it builds a solid foundation for long-term growth and value appreciation.

Underrated weed stock

Supreme Cannabis remains underrated. However, the company is taking deliberate steps to grow and build an active business and authentic brand.

The audited fourth-quarter results aren’t due until September 17, 2019, but Supreme Cannabis already gave investors a glimpse of what to expect. Revenue is expected to increase by 449% or nearly double versus Q4 2018 revenue.

Navdeep Dhaliwal, Supreme Cannabis’ CEO, is confident that the measured approach to capital deployment and brand-building will set the company apart. Revenue growth will continue throughout 2020.

One of Supreme Cannabis’ operating assets, 7ACRES, will scale production and introduce new and higher-margin products. The launching of 7ACRES premium oil pod for the PAX Era is coming son. Other significant operating assets and cannabis brands are Truverra, Blissco, Medigrow, and Super Heights.

Cambium Plant Sciences will handle the research and development for Supreme Cannabis. This R&D facility focuses on the development of the next generation of premium cannabis genetics and proprietary cultivation processes.

Supreme Cannabis is forecasting net revenue of $150 to $180 million in 2020. Also, this quarter, 7ACRES’ transition from a wholesale business to premium consumer brand will be complete.  Analysts see FIRE rising from $1.46 to $4.50 or an upside of 208% in the next twelve months.

Colossal gains in the future

You shouldn’t belittle Alcanna and Supreme Cannabis, however. Both companies are transitioning and growing and could well outperform the more significant but problematic cannabis producers.

If you’re after colossal gains in the cannabis sector, invest in Alcanna and Supreme while the stocks are affordable. These marvelous marijuana stocks in the making will command higher prices soon.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »